Radical thoracic radiotherapy is a mainstay in the treatment of non-small cell lung cancer (NSCLC); however, the effect of cardiac doses on survival is becoming increasingly important, as highlighted by the RTOG 0617 study (NCT00533949). Here, Matthew Hatton, MBChB, MRCP, FRCP, FRCR, of the Sheffield Teaching Hospitals NHS Foundation Trust, Sheffield, UK, discusses his groups exciting work investigating the effect of different cardiac doses of radiotherapy on patient outcomes. Dr Hatton highlights the significance of this work, being different compared with reported study outcomes, due to the use of accelerated and sequential radiotherapy regimens in the real-world setting. He then covers the interesting results observed, indicating that cardiac dosing may have a bigger impact than initially thought, before covering the next steps of this work and potential short-term considerations. This video was recorded at the European Lung Cancer Congress (ELCC) 2018, held in Geneva, Switzerland.
Cardiac doses of radical radiotherapy impact survival in NSCLC: a real-world analysis
